1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. Supernus Pharmaceuticals Acquires Sage Therapeutics

M&A Deal Summary

Supernus Pharmaceuticals Acquires Sage Therapeutics

On June 16, 2025, Supernus Pharmaceuticals acquired leisure company Sage Therapeutics for 795M USD

Acquisition Highlights
  • This is Supernus Pharmaceuticals’ 1st transaction in the Leisure sector.
  • This is Supernus Pharmaceuticals’ largest (disclosed) transaction.
  • This is Supernus Pharmaceuticals’ 4th transaction in the United States.
  • This is Supernus Pharmaceuticals’ 1st transaction in Massachusetts.

M&A Deal Summary
Date 2025-06-16
Target Sage Therapeutics
Sector Leisure
Buyer(s) Supernus Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 795M USD
Advisor(s) Goldman Sachs (Financial)
Kirkland & Ellis (Legal)

Target

Sage Therapeutics

Cambridge, Massachusetts, United States
Sage Therapeutics is a biopharmaceutical company that delivers brain health medicines. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Supernus Pharmaceuticals

Rockville, Maryland, United States
Category Company
Founded 2005
Sector Life Science
Employees674
Revenue 662M USD (2024)
DESCRIPTION

Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. Supernus Pharmaceuticals was founded in 2005 and is based in Rockville, Maryland.

DEAL STATS #
Overall 4 of 4
Sector: Leisure M&A 1 of 1
Type: Add-on Acquisition M&A Deals 3 of 3
State: Massachusetts M&A 1 of 1
Country: United States M&A 4 of 4
Year: 2025 M&A 1 of 1
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-10-11 Adamas

Emeryville, California, United States

Adamas is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system (CNS). Its achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas was founded in 2000 and is based in Emeryville, California.

Buy $450M
Mergr

Solution for

Product

Company

Legal